Provided herein are compounds of Formula (I) and uses thereof for inhibiting the activity of D-amino acid oxidase (DAAO) or treating diseases or disorders associated with DAAO, such as a central nervous system (CNS) disorder, obesity, diabetes, or hyperlipidemia. Also provided in the present disclosure are methods of synthesizing the Formula (I) compounds described herein. ##STR00001##

Provided is a mono-tin organic compound for the synthesis of sucrose-6-carboxylate. The compound has a structure shown in formula (1), wherein R.sub.1, R.sub.2, and R.sub.3 each are independently selected from the group consisting of C.sub.1 to C.sub.8 linear or branched saturated alkyl, C.sub.2 to C.sub.8 linear or branched unsaturated alkyl, C.sub.3 to C.sub.8 substituted or unsubstituted saturated cycloalkyl, C.sub.3 to C.sub.8 substituted or unsubstituted unsaturated cycloalkyl, and C.sub.6 to C.sub.12 aryl or substituted aryl; and R.sub.4 is selected from the group consisting of C.sub.1 to C.sub.6 linear or branched saturated alkyl and C.sub.6 to C.sub.12 aryl or substituted aryl.

Provided is a mono-tin organic compound for the synthesis of sucrose-6-carboxylate. The compound has a structure shown in formula (1), wherein R.sub.1, R.sub.2, and R.sub.3 each are independently selected from the group consisting of C.sub.1 to C.sub.8 linear or branched saturated alkyl, C.sub.2 to C.sub.8 linear or branched unsaturated alkyl, C.sub.3 to C.sub.8 substituted or unsubstituted saturated cycloalkyl, C.sub.3 to C.sub.8 substituted or unsubstituted unsaturated cycloalkyl, and C.sub.6 to C.sub.12 aryl or substituted aryl; and R.sub.4 is selected from the group consisting of C.sub.1 to C.sub.6 linear or branched saturated alkyl and C.sub.6 to C.sub.12 aryl or substituted aryl.

Provided herein are potent compounds of Formula (I) and uses thereof for inhibiting the activity of D-amino acid oxidase (DAAO) or treating diseases or disorders associated with DAAO, such as a central nervous system (CNS) disorder, pain, obesity, diabetes, or hyperlipidemia. Also provided in the present disclosure are methods of synthesizing the Formula (I) compounds described herein. (I)

##STR00001##

The present disclosure relates to a thiazole-5-carboxylic acid derivative represented by Formula (I), a stereoisomer and/or pharmaceutically acceptable salt thereof. The compound of Formula (I), the stereoisomer and/or pharmaceutically acceptable salt thereof of the present disclosure can be used to prepare a medicament for preventing or treating hyperuricemia and/or gout, and can be prepared into dosage forms for various administration routes. The compounds provided in the present disclosure have good tolerance, safety and excellent uric acid-lowering activity.

##STR00001##

A new biomaterial is disclosed. The biomaterial is prepared by mixing glycosaminoglycan with a phosphoric acid, phosphate ester, or salt or derivative thereof under the action of a catalyst in a liquid reaction medium at a pH of 2.1 to 4.9. The obtained material is capable of enhancing the immunological resistance in human and in animals, treating diseases in human and in animals caused by viruses or bacteria, strengthening the anti-stress ability of animals, improving the appetite of animals, promoting the growth of animals, inhibiting the growth of tumor, lowering blood fat level, as well as preventing and treating viral diseases in plants.

A new biomaterial is disclosed. The biomaterial is prepared by mixing glycosaminoglycan with a phosphoric acid, phosphate ester, or salt or derivative thereof under the action of a catalyst in a liquid reaction medium at a pH of 2.1 to 4.9. The obtained material is capable of enhancing the immunological resistance in human and in animals, treating diseases in human and in animals caused by viruses or bacteria, strengthening the anti-stress ability of animals, improving the appetite of animals, promoting the growth of animals, inhibiting the growth of tumor, lowering blood fat level, as well as preventing and treating viral diseases in plants.

The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.

The present invention provides sialic acid analogs and their compositions useful for the treatment of sialic acid deficiencies.

An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.